18.06.2025 14:37

Eyenovia, a Nasdaq-listed biotechnology company, has made a significant strategic move into the blockchain space. The firm announced a $50 million investment in Hyperliquid (HYPE), a move that positions it as the first publicly traded U.S. company to hold a native token treasury. This bold investment signals a diversification strategy beyond its core biotech operations.

This investment isn't simply a passive holding; it represents a substantial commitment to the Hyperliquid ecosystem. With the appointment of Hyunsu Jung as its new Chief Information Officer, Eyenovia is actively developing its blockchain strategy. Jung's leadership will oversee the expansion of validator nodes and the overall integration of blockchain technology within the company.

Further solidifying its involvement, Eyenovia plans a rebranding to Hyperion DeFi. This comprehensive rebranding will encompass a ticker symbol change to HYPD, reflecting its expanded operations in both biotechnology and decentralized finance. This dual focus underscores the company’s vision of integrating its traditional business model with the innovative opportunities offered by blockchain technology.

The strategic alliance with Anchorage Digital, a leading digital asset custodian, is crucial to Eyenovia’s blockchain strategy. Through this partnership, Eyenovia will operate as a validator on the Hyperliquid blockchain, aiming to generate yield from transaction fees while simultaneously contributing to the security and stability of the network. This multifaceted approach maximizes the value derived from the HYPE token investment. In essence, Eyenovia's actions demonstrate a forward-thinking approach, blending traditional business practices with cutting-edge blockchain technology for long-term growth.